Figure 1B shows the location of the pharmacophoric points identified for the interaction of ponatinib with the RIPK2 active site and the proposed binding modes of the ligands with the lowest binding free energies, respectively. (jpet.aspetjournals.org)
Thus, the arrangement of benzene rings found in RIPK2 inhibitor 1 resembles the geometry of the corresponding aromatic rings in ponatinib bound to RIPK2. (jpet.aspetjournals.org)
Updated findings from the pivotal phase II PACE trial show sustained benefit of the investigational BCR - ABL tyrosine kinase inhibitor ponatinib in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia or Philadelphia chromosome - positive acute lymphoblastic leukemia. (cancernetwork.com)